Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib

被引：0

作者：

Y. Mishima

Y. Terui

K. Takeuchi

E. Nagasaki

M. Yokoyama

N. Mizunuma

S. Takahashi

K. Yamada

T. Fukunaga

J. Yamamoto

T. Yamaguchi

Y. Kato

K. Hatake

机构：

[1] Japanese Foundation for Cancer Research,Division of Medical Oncology, Cancer Institute Hospital

[2] Japanese Foundation for Cancer Research,Division of Pathology, Cancer Institute Hospital

[3] Japanese Foundation for Cancer Research,Division of Radiology, Cancer Institute Hospital

[4] Japanese Foundation for Cancer Research,Division of Gastroenterological Surgery, Cancer Institute Hospital

来源：

Targeted Oncology | 2006年 / 1卷

关键词：

GIST; CML; Imatinib; BCR-ABL; c-KIT;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Imatinib mesylate (imatinib, STI571, Gleevec; Novartis Pharma) is an orally administered competitive inhibitor of BCR-ABL tyrosine kinase that has demonstrated significant efficacy in chronic myelogenous leukemia (CML). Imatinib is also a potent inhibitor of the receptor-type KIT tyrosine kinase with demonstrated benefits in KIT-expressing gastrointestinal stromal tumors (GISTs). This article presents the case of a patient with simultaneous occurrence of CML and GIST who was treated with the single agent imatinib. To our knowledge, this is the first report of simultaneous occurrence of these two malignancies and of the efficacy of imatinib in concurrent treatment of both neoplasms in a single patient.

引用

页码：168 / 171

页数：3

共 28 条

[1]

Druker BJ(2001)Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031-1037

[2]

Talpaz M(2002)Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review Eur J Cancer 38 S39-S51

[3]

Resta DJ(2002)Identification and treatment of chemo-resistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571) Eur J Cancer 38 S52-S59

[4]

Miettinen M(2002)Management of malignant gastrointestinal stromal tumours Lancet Oncol 3 655-664

[5]

Majidi M(2004)Biology of gastrointestinal stromal tumors J Clin Oncol 22 3813-3825

[6]

Lasota J(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472-480

[7]

Demetri GD(2004)High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2873-2878

[8]

Joensuu H(2004)Use of c-KIT/PDGFRα mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 40 689-695

[9]

Fletcher C(2002)Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 3898-3905

[10]

Dimitrijevic S(2004)Prognostic significance of c-KIT mutation in localized gastrointestinal stromal tumors Clin Cancer Res 10 3076-3081

← 1 2 3 →